Zenas BioPharma Future Growth

Future criteria checks 0/6

Zenas BioPharma's earnings are forecast to decline at 6.8% per annum while its annual revenue is expected to grow at 79.1% per year. EPS is expected to grow by 54.6% per annum. Return on equity is forecast to be -101.1% in 3 years.

Key information

-6.8%

Earnings growth rate

54.6%

EPS growth rate

Biotechs earnings growth	27.6%
Revenue growth rate	79.1%
Future return on equity	-101.1%
Analyst coverage	Low
Last updated	16 Dec 2024

Recent future growth updates

No updates

Recent updates

Zenas Bio: Recent IPO With Late-Stage Candidate

Oct 22

Earnings and Revenue Growth Forecasts

NasdaqGS:ZBIO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	34	-205	-143	-109	3
12/31/2025	N/A	-182	-167	-171	3
12/31/2024	N/A	-144	-141	-143	3
9/30/2024	N/A	-129	-97	-97	N/A
6/30/2024	50	-55	-34	-34	N/A
3/31/2024	50	-46	-24	-24	N/A
12/31/2023	50	-37	-31	-31	N/A
9/30/2023	50	-32	-33	-32	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZBIO is forecast to have no revenue next year.

High Growth Revenue: ZBIO is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ZBIO is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 07:22
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zenas BioPharma, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yigal Nochomovitz	Citigroup Inc
Yatin Suneja	Guggenheim Securities, LLC
Matthew Caufield	H.C. Wainwright & Co.